Radiomics.bio
Insight-based
decision making

Diseases and
therapeutic areas

Industry
and Pharma

Healthcare
professionals

Scientific
researchers

About Radiomics.bio


Radiomics.bio is an imaging research organisation built upon the unparallel experience of its founders, pioneers of the radiomics science.
 
Radiomics.bio focuses on AI powered healthcare, with a unique expertise in Radiomics, Deep Learning & Federated Learning applied to oncology and other therapeutic areas. Through our proprietary advanced image analysis technology, we aim to unravel the gold mine of hidden data information embedded in standard medical images.
 
Radiomics enables insight-based decision making to optimise clinical trials and drug development studies and to provide clinicians with a patient-centered approach based on personalized medicine. With these objectives, Radiomics.bio’s R&D team is continuously working on new solutions, in collaboration with multiple national and international partners.

We can help you

optimise

Optimise

Your clinical trials (in terms of costs and time)

detect

Detect

The subtlest signals of drugs efficacy and safety risk
facilitate

Facilitate

Your crucial
go / no-go
decisions
identify

Identify

Patients likely to respond to your treatment
strenghten

Strengthen

Your points
in pay for outcome scenarios

Why Radiomics.bio

Experience

Our scientists and clinicians are the ones who invented radiomics and have unparalleled experience and international recognition in this AI field.

Outreach

Radiomics.bio has clients and partners in the EU, the US, Africa and Australia. Radiomics has a permanent presence in North America with a fully owned affiliate in Toronto.

IP Portfolio

Radiomics.bio's comprehensive IP portfolio includes both granted and pending international (EU/US) patents.

People

Radiomics.bio's team is composed of a multicultural and multidisciplinary set of people, specialized in a broad range of domains always enthusiastic in addressing clients and partner's needs. 

Publications

Radiomics.bio has numerous publications in high impact journals such as Nature Reviews, Clinical Oncology, Annals of Oncology and many more. 

Latest news

news
  • February 29th, 2024

From Images to Impact: Radiomics' Solutions to Challenges in Immunotherapy


Up to 30% of patients may experience hyper progression following immunotherapy. Identifying patients who will actually benefit from immunotherapy is intrinsic to achieving optimal outcomes. Radiomics can offer a solution to this problem by analysing the phenotypical changes in lesions and organs that may occur following the initiation of a treatment.

press
  • September 5th, 2023

Pilot project at the Jewish General Hospital aims to accelerate access to new and highly effective treatments for cancer patients


Pilot project at the Jewish General Hospital aims to accelerate access to new and highly effective treatments for cancer patients

press
  • April 7th, 2023

Belgian biotech companies DeuterOncology and Radiomics combine their expertise to improve cancer therapy


DeuterOncology joins forces with Radiomics to develop a clinical tool to predict patient response to treatment.